United Therapeutics (UTH) Stock Forecast & Price Target
4 Followers
UTH Analyst Ratings
Moderate Buy
11Buy2Hold1Sell
Based on 14 analysts giving stock ratings to United Therapeutics in the past 3 months
UTH Stock 12 Month Forecast
Average Price Target
EUR 604.91▲(13.53% Upside)Based on 14 Wall Street analysts offering 12 month price targets for United Therapeutics in the last 3 months. The average price target is EUR 604.91 with a high forecast of EUR 755.26 and a low forecast of EUR 326.98. The average price target represents a 13.53% change from the last price of EUR 532.80.
Past 12 Months12 Month ForecastJan2026Oct2026
HighEUR 755.26
AverageEUR 604.91
LowEUR 326.98
Highest Price TargetHighestEUR 755.26Average Price TargetEUR 604.91Lowest Price TargetLowestEUR 326.98
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Benjamin Burnett | Wells Fargo | EUR 621.98→EUR 624.64 | buy | 17.24%Upside | Assigned | 11/05/26 | ||
| Jason Gerberry | Bank of America Securities | EUR 496.69→EUR 577.55 | hold | 8.40%Upside | Reiterated | 11/04/26 | ||
| Julian Harrison | BTIG | EUR 646.86→EUR 682.40 | buy | 28.08%Upside | Reiterated | 11/04/26 | ||
| Lisa Walter | RBC Capital | EUR 619.31→EUR 644.19 | buy | 20.91%Upside | Reiterated | 11/04/26 | ||
| Jessica Fye | J.P. Morgan | EUR 630.86→EUR 617.54 | buy | 15.90%Upside | Assigned | 10/28/26 | ||
| Olivia Brayer | Cantor Fitzgerald | EUR 621.98→EUR 755.26 | buy | 41.75%Upside | Reiterated | 10/26/26 | ||
| Roanna Ruiz | Leerink Partners | EUR 608.65→EUR 644.19 | buy | 20.91%Upside | Assigned | 10/20/26 | ||
| Tiago Fauth | Raymond James | EUR 608.65→EUR 637.08 | buy | 19.57%Upside | Reiterated | 10/20/26 | ||
| Andrea Newkirk | Goldman Sachs | EUR 285.22→EUR 326.98 | sell | -38.63%Downside | Reiterated | 10/15/26 | ||
| Ashwani Verma | UBS | EUR 644.19 | buy | 20.91%Upside | Reiterated | 10/13/26 | ||
| Terence Flynn | Morgan Stanley | EUR 502.91 | hold | -5.61%Downside | Reiterated | 10/07/26 | ||
| Roger Song | Jefferies | EUR 625.53 | buy | 17.40%Upside | Reiterated | 10/01/26 | ||
| Joseph Thome | TD Cowen | EUR 599.76 | buy | 12.57%Upside | Reiterated | 09/02/26 | ||
| Andrew Fein | H.C. Wainwright | EUR 586.44 | buy | 10.07%Upside | Reiterated | 08/06/26 | ||
| Jasper Hellweg | Argus Research | EUR 497.58 | buy | -6.61%Downside | Assigned | 03/03/26 |
| Rating | Follow | Article | |||
|---|---|---|---|---|---|
| Benjamin BurnettWells Fargo | BuyAssignedEUR 621.98→EUR 624.64 | 11/05/26 | 17.24%Upside | ||
| Jason GerberryBank of America Securities | HoldReiteratedEUR 496.69→EUR 577.55 | 11/04/26 | 8.40%Upside | ||
| Julian HarrisonBTIG | BuyReiteratedEUR 646.86→EUR 682.40 | 11/04/26 | 28.08%Upside | ||
| Lisa WalterRBC Capital | BuyReiteratedEUR 619.31→EUR 644.19 | 11/04/26 | 20.91%Upside | ||
| Jessica FyeJ.P. Morgan | BuyAssignedEUR 630.86→EUR 617.54 | 10/28/26 | 15.90%Upside | ||
| Olivia BrayerCantor Fitzgerald | BuyReiteratedEUR 621.98→EUR 755.26 | 10/26/26 | 41.75%Upside | ||
| Roanna RuizLeerink Partners | BuyAssignedEUR 608.65→EUR 644.19 | 10/20/26 | 20.91%Upside | ||
| Tiago FauthRaymond James | BuyReiteratedEUR 608.65→EUR 637.08 | 10/20/26 | 19.57%Upside | ||
| Andrea NewkirkGoldman Sachs | SellReiteratedEUR 285.22→EUR 326.98 | 10/15/26 | -38.63%Downside | ||
| Ashwani VermaUBS | BuyReiteratedEUR 644.19 | 10/13/26 | 20.91%Upside | ||
| Terence FlynnMorgan Stanley | HoldReiteratedEUR 502.91 | 10/07/26 | -5.61%Downside | ||
| Roger SongJefferies | BuyReiteratedEUR 625.53 | 10/01/26 | 17.40%Upside | ||
| Joseph ThomeTD Cowen | BuyReiteratedEUR 599.76 | 09/02/26 | 12.57%Upside | ||
| Andrew FeinH.C. Wainwright | BuyReiteratedEUR 586.44 | 08/06/26 | 10.07%Upside | ||
| Jasper HellwegArgus Research | BuyAssignedEUR 497.58 | 03/03/26 | -6.61%Downside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering United Therapeutics
3 Months
Success Rate16/19 ratings generated profit
84%
Average Return
+14.57%
Copying Roanna Ruiz's trades and holding each position for 3 Months would result in 84.21% of your transactions generating a profit, with an average return of +14.57% per trade.
1 Year
Success Rate16/16 ratings generated profit
100%
Average Return
+31.64%
Copying Roger Song's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +31.64% per trade.
2 Years
Success Rate19/19 ratings generated profit
100%
Average Return
+75.99%
Copying Roanna Ruiz's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +75.99% per trade.
UTH Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 16 | 14 | 16 | 25 | 21 |
| Hold | 4 | 3 | 2 | 3 | 3 |
| Sell | 0 | 0 | 1 | 2 | 2 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 20 | 17 | 19 | 30 | 26 |
In the current month, UTH has received 21 Buy Ratings, 3 Hold Ratings, and 2 Sell Ratings. UTH average Analyst price target in the past 3 months is 604.91.
UTH Financial Forecast
HighEUR 9.81
ConsensusEUR 5.04
LowEUR 2.38
UTH Earnings Forecast
Next quarter’s earnings estimate for UTH is EUR 5.04 with a range of EUR 2.38 to EUR 9.81. The previous quarter’s EPS was EUR 5.07. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighEUR 1.03B
ConsensusEUR 759M
LowEUR 616M
UTH Sales Forecast
Next quarter’s sales forecast for UTH is EUR 758.79M with a range of EUR 615.92M to EUR 1.03B. The previous quarter’s sales results were EUR 739.71M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
UTH Stock Forecast FAQ
What is DE:UTH’s average 12-month price target, according to analysts?
Based on analyst ratings, United Therapeutics’s 12-month average price target is €604.91.
What is DE:UTH’s upside potential, based on the analysts’ average price target?
United Therapeutics has 13.53% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is United Therapeutics a Buy, Sell or Hold?
United Therapeutics has a consensus rating of Moderate Buy, which is based on 11 buy ratings, 2 hold ratings and 1 sell ratings.
What is United Therapeutics’s share price target?
The average share price target for United Therapeutics is €604.91. This is based on 14 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €755.26, and the lowest forecast is €326.98. The average share price target represents a 13.53% increase from the current price of €532.8.
What do analysts say about United Therapeutics?
United Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Street analysts.
How can I buy shares of United Therapeutics?
To buy shares of DE:UTH, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
